Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:55:51.397Z.
Consensus retrieved: 2026-10-06T08:56:37.917Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:55:51.397Z.
Quote observation: 2026-10-06T14:55:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9de0dbfadb283a207fe687abae4d6c7414f83280ed3d33a9edf26fe3e5e7dd3
Forward PE Ratio (N/A) = Dated Quote Price ($3.29) / Consensus Forward EPS ($-0.18)
FORWARD PE RATIO
N/A
Ardelyx, Inc.
Market Cap
$813.96M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ardelyx, Inc. (ARDX) | $813.96M | N/A |
| Apnimed, Inc. (APMD)vs › | $807.90M | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 10.81 |
| Jade Biosciences, Inc. (JBIO)vs › | $821.00M | N/A |
| Alumis Inc. (ALMS)vs › | $830.70M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | N/A |
| AdaptHealth Corp. (AHCO)vs › | $784.35M | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.73M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.29, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.18 | $-0.24 – $-0.09 | 8 | n/m |
| 2027-12-31 | $0.26 | $0.03 – $0.68 | 8 | 12.7x |
| 2028-12-31 | $0.81 | $0.35 – $1.31 | 7 | 4.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
